X @The Wall Street Journal

Clinical Trial Results - Novo Nordisk shares experienced a sharp decline following the announcement that a pill containing the active ingredient found in Ozempic and Wegovy failed to demonstrate efficacy in slowing Alzheimer's disease progression in two late-stage clinical trials [1] Pharmaceutical Industry Implications - The unsuccessful trial results highlight the challenges and risks associated with drug development in the treatment of Alzheimer's disease [1]